Session 84 - CROI 2007

Session 84 Poster Abstracts
T-Cell Vaccine Design: New Vectors and Preclinical Testing
Monday, 1 - 4 pm
Poster Hall

457	Reciprocal Cross Heterologous Immunity between Human Endogenous Retrovirus and HIV-1 Provides a Novel HIV-1 Vaccine Strategy Keith Garrison*¹, B Jones², D Meiklejohn¹, L Ndhlovu¹, A Agrawal¹, F Hecht¹, S Rakoff-Nahoum³, J Lenz⁴, M Ostrowski², and D Nixon¹ ¹Univ of California, San Francisco, US; ²Univ of Toronto, Canada; ³Yale Univ, New Haven, CT, US; and ⁴Albert Einstein Coll of Med, Bronx, NY, US
458	Foamy Virus Vectors Persistently Express High Levels of HIV-1 gag: Potential for an HIV Vaccine W. David Hardy^1,2, W. David Hardy^1,2, C Liu¹, Y Xi², T Folks³, and I Chen² ¹Cedars-Sinai Med Ctr, Los Angeles, CA, US; ²David Geffen Sch of Med, Univ of California, Los Angeles, US; and ³CDC, Atlanta, GA, US
459	Characterization of a Single-cycle SIV Vaccine Candidate Yuyang Tang* and R Swanstrom Univ of North Carolina at Chapel Hill, US
460	Recombinant Simian Varicella Virus Containing Simian Immunodeficiency Genes Are Immunogenic in Nonhuman Primates Vicki Traina-Dorge*¹, R Lorino¹, M Singletary¹, Y Ou², and W Gray² ¹Tulane Natl Primate Res Ctr, Tulane Univ, Covington, LA, US and ²Univ of Arkansas for Med Sci, Little Rock, US
461	Design and Testing of Coxsackievirus-based Vaccine Vectors to Express HIV-1 Nef and Gag John Miller*, O Yang, H Ng, Y Geng, and P Krogstad David Geffen Sch of Med, Univ of California, Los Angeles, US
462	Peripheral and Tissue Cytokine Responses Associated with Acute SIV Infection and Vaccine-induced Immunity Pratip Chattopadhyay*, J Mattapallil, K Song, and M Roederer Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US
463	Long-term CTL-based SIV Control by Vaccine-based Non-sterile Protection in Rhesus Macaques Miki Kawada*¹, T Tsukamoto¹, H Yamamoto¹, A Takeda¹, D Watkins², and T Matano¹ ¹Univ of Tokyo, Japan and ²Univ of Wisconsin, Madison, US
464	High Levels of SIV-specific CD8⁺ T cells in the Mucosal Tissues of Rhesus Macaques Immunized with MVA-vectored Candidate AIDS Vaccines Richard Dunham*¹, B Sumpter¹, M McQuoid¹, J Engram², G Makedonas², M Betts², J Altman¹, M Feinberg³, D Garber¹, G Silvestri^1,2, and G Silvestri^1,2 ¹Emory Vaccine Ctr and Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US; ²Univ of Pennsylvania, Philadelphia, US; and ³Merck Vaccine Div, West Point, PA, US
465	Nasal Vaccination of Rhesus Macaques with Combined Proviral SIV DNA-MVA Provides Better Protection from Disease Progression than a Similar Intramuscular Vaccination Mariana Manrique*¹, P Kozlowski¹, E Micewicz¹, D Montefiori², A Carville³, K Mansfield³, and A Aldovini¹ ¹Children's Hosp, Harvard Med Sch, Boston, MA, US; ²Duke Univ, Durham, NC, US; and ³New England Regional Primate Res Ctr, Harvard Med Sch, Southborough, MA, US
466	Protection from SIV Challenge in a Live-attenuated Lentivirus Vaccine Model Is Associated with Increased Survival Capacity in T Cells, Allowing Maintenance of Specific Polyfunctional CD8⁺ T Cells and T-cell Help Meritxell Genescà^1,2, Meritxell Genescà^1,2, J Li^1,2, J Li^1,2, B Chohan^1,2, B Chohan^1,2, K Bost^1,2, K Bost^1,2, T Rourke^1,2, T Rourke^1,2, M McChesney², C Miller^1,2, and C Miller^1,2 ¹Ctr for Comparative Med, Univ of California, Davis, US and ²California Natl Primate Res Ctr, Univ of California, Davis, US
467	CD8 T-cell Responses to Computationally Derived HIV Vaccine Constructs in an HIV-1B-infected Cohort David Nickle*¹, N Frahm², M Rolland¹, N Jojic³, C Brander², J Mullins¹, D Heckerman^2,4, and D Heckerman^2,4 ¹Univ of Washington Sch of Med, Seattle, US; ²Massachusetts Gen Hosp, Charlestown, US; ³Microsoft Res, Redmond, WA, US; and ⁴Univ of Washington, Seattle, US
468	Abrogation of in vivo Efficacy of Vaccine-induced CTL against Heterologous SIV Challenge by a Single Amino Acid Change in Viral Epitope Flanking Region C Moriya, M Kawada, T Tsukamoto, H Yamamoto, A Takeda, and Tetsuro Matano* Univ Tokyo, Japan